Biosimilars are nonpatented biologic products that are similar to reference biologic agents in structure, function, activity, safety, and efficacy. In 2014, investigators from the RAND Corporation, a prominent policy think tank, predicted that the introduction of biosimilars could result in up to $44.2 billion worth of savings from 2014 to 2024 in the United States.1 Thus, they envisioned that the emergence of biosimilar drugs has the potential to create substantial savings for the nation’s health care system. This estimate was derived from a model identifying potential price savings based on 4 factors: safety and effectiveness of a biosimilar in comparison with the branded biologic; payers’ willingness to pay for biosimilars relative to the branded biologic; the extent to which patients, physicians, and payers will adopt biosimilars; and barriers to entry faced by biosimilar makers.1
Yang YT, Chen B, Bennett CL. Biosimilars—Curb Your Enthusiasm. JAMA Oncol. 2017;3(11):1467–1468. doi:10.1001/jamaoncol.2017.1530
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.